Skip to main content

Table 5 Regression models for recrudescence and new infection using data from Burkina Faso (n = 810) [18]

From: Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis

 

Observed proportion of events

Cause-specific Cox proportional hazard model

Fine and Gray’s sub-distribution hazard model

Cause-specific HR [95% confidence interval]

P-value

Sub-distribution HR [95% confidence interval]

P-value

Model for recrudescence

 Age (/yearly increase)

4.9% (40/810)

0.99 [0.77–1.29]

0.965

1.00 [0.80–1.25]

0.990

 Baseline parasitaemia (/µL) (tenfold increase)

4.9% (40/810)

1.67 [0.88–3.16]

0.114

1.44 [0.84–2.46]

0.190

 Treatment (ref = DP)

3.2% (7/221)

    

  AL

8.2% (24/294)

4.02 [1.72–9.43]

0.001

2.85 [1.24–6.57]

0.014

  ASAQ

3.1% (9/295)

1.12 [0.42–2.99]

0.829

1.01 [0.38–2.69]

0.980

Model for new infection

 Age (/yearly increase)

29.4% (238/810)

1.08[0.98–1.21]

0.121

1.08[0.99–1.19]

0.093

 Baseline parasitaemia (/µL) (tenfold increase)

29.4% (238/810)

1.52[1.18–1.97]

0.001

1.40[1.10–1.78]

0.006

 Treatment (ref = DP)

10.0% (22/221)

    

  AL

48.3% (142/294)

8.05[5.12–12.67]

< 0.001

6.51[4.27–9.94]

< 0.001

  ASAQ

25.1% (74/295)

3.03[1.88–4.88]

< 0.001

2.83[1.80–4.44]

< 0.001

  1. AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine, ASAQ artesunate–amodiaquine